AstraZeneca seeks to cure cancer with artificial intelligence

Astarazenka, one of the pharmaceutical companies that has succeeded in producing a vaccine for Covid-19, is collaborating with an artificial intelligence company based in the United States of America called Absci to find cancer antibodies. These two companies are both active in the pharmaceutical field and have a history of useful products in this field.

According to Hoshio, AstraZeneca will invest up to 247 million dollars in Absci, which according to the analysis was the largest amount of trading investment in artificial intelligence in 2023. This issue is considered an important point considering the decrease in the amount of investments on artificial intelligence since 2019 due to the maturity of the market and shows the importance of this project for both companies. The goal of this collaboration is to create a zero-shot generative artificial intelligence that will help experts create new therapeutic antibodies for cancer. AstraZeneca Company has not yet specified the type or types of cancer under study, and detailed information about this issue is not available.

Absci is one of the active companies in the field of artificial intelligence, which currently participates in 17 active projects. The company is one of the pioneers of generative artificial intelligence focused on health care, whose laboratory in New York operates in the field of comparison of millions of protein samples with the aim of antibody discovery. This new technology is very promising for the future treatment of rare diseases; Because artificial intelligence helps to reduce the costs of this process and save time, and in this way brings the possibility of drug tests that no company would be willing to do without artificial intelligence due to the lack of affordability. Absci claims on its website that AI can screen billions of cells every week and have a huge impact on the research process. The company also signed a deal earlier this year with bioinformatics company M2GEN to develop antibodies.

Astarazenka, one of the pharmaceutical companies that has succeeded in producing a vaccine for Covid-19, is collaborating with an artificial intelligence company based in the United States of America called Absci to find cancer antibodies. These two companies are both active in the pharmaceutical field and have a history of useful products in this field.

According to Hoshio, AstraZeneca will invest up to 247 million dollars in Absci, which according to the analysis was the largest amount of trading investment in artificial intelligence in 2023. This issue is considered an important point considering the decrease in the amount of investments in artificial intelligence since 2019 due to the maturity of the market and shows the importance of this project for both companies. The goal of this collaboration is to create a zero-shot generative artificial intelligence that will help experts create new therapeutic antibodies for cancer. AstraZeneca Company has not yet specified the type or types of cancer under study, and detailed information about this issue is not available.

Absci is one of the active companies in the field of artificial intelligence, which currently participates in 17 active projects. The company is one of the pioneers of generative artificial intelligence focused on health care, whose laboratory in New York operates in the field of comparison of millions of protein samples with the aim of antibody discovery. This new technology is very promising for the future treatment of rare diseases; Because artificial intelligence helps to reduce the costs of this process and save time, and in this way brings the possibility of drug tests that no company would be willing to do without artificial intelligence due to the lack of affordability. Absci claims on its website that AI can screen billions of cells every week and have a huge impact on the research process. The company also signed a deal earlier this year with bioinformatics company M2GEN to develop antibodies.